Benzalkonium chloride (BAK) compounds are commonly used in topical ophthalmic products as preservatives and stabilizers. BAK mixtures containing several compounds with different alkyl chain lengths are typically used. However, in chronic eye conditions, such as dry eye disease and glaucoma, the accumulation of adverse effects of BAKs was observed. Hence, preservative-free eye drops formulations are preferred. On the other hand, selected long-chain BAKs, particularly cetalkonium chloride, exhibit therapeutic functions, promoting epithelium wound healing and tear film stability. Nevertheless, the mechanism of BAKs influence on the tear film is not fully understood. By employing in vitro experimental and in silico simulation techniques, we elucidate the action of BAKs and demonstrate that long-chain BAKs accumulate in the lipid layer of the tear film model, stabilizing it in a concentration-dependent fashion. In contrast, short-chain BAKs interacting with the lipid layer compromise the tear film model stability. These findings are relevant for topical ophthalmic drug formulation and delivery in the context of selecting proper BAK species and understanding the dose dependency for tear film stability.
Influence of BAKs on Tear Film Lipid Layer: in vitro and in silico models.
Kamila Riedlová,Maria Chiara Saija,A. Olżyńska,P. Jurkiewicz,Philippe Daul,J. Garrigue,Lukasz Cwiklik
Published 2023 in European journal of pharmaceutics and biopharmaceutics
ABSTRACT
PUBLICATION RECORD
- Publication year
2023
- Venue
European journal of pharmaceutics and biopharmaceutics
- Publication date
2023-03-01
- Fields of study
Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-40 of 40 references · Page 1 of 1
CITED BY
Showing 1-12 of 12 citing papers · Page 1 of 1